Production Method 1

606143-52-6

Reaction Conditions

Reference

Combinations of MEK kinase and HH inhibitors for cancer treatment

, World Intellectual Property Organization, , ,

Production Method 2

606143-52-6

Reaction Conditions

Reference

Crystal forms of a 1H-benzimidazole-6-carboxamide hydrogen sulfate salt

, World Intellectual Property Organization, , ,

Selumetinib Preparation Products

• Selumetinib (606143-52-6)

• 1. Applying support-vector machine learning algorithms toward predicting host–guest interactions with cucurbit[7]uril
  Anthony Tabet,Thomas Gebhart,Guanglu Wu,Charlie Readman,Merrick Pierson Smela,Vijay K. Rana,Cole Baker,Harry Bulstrode,Polina Anikeeva,David H. Rowitch,Oren A. Scherman Phys. Chem. Chem. Phys. 2020 22 14976
• 2. Simultaneously monitoring endogenous MAPK members in single living cells by multi-channel fluorescence correlation spectroscopy
  Liyun Deng,Xiangyi Huang,Chaoqing Dong,Jicun Ren Analyst 2021 146 2581
• 3. Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma
  Igor F. Tsigelny,Valentina L. Kouznetsova,Pengfei Jiang,Sandeep C. Pingle,Santosh Kesari Mol. BioSyst. 2015 11 1012
• 4. Insights into auto-S-fatty acylation: targets, druggability, and inhibitors
  Lu Hu,Zhipeng Tao,Xu Wu RSC Chem. Biol. 2021 2 1567
• 5. Small molecule inhibitors in pancreatic cancer
  Jufeng Sun,Cecilia C. Russell,Christopher J. Scarlett,Adam McCluskey RSC Med. Chem. 2020 11 164

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles
• Other Chemical additives Functional Additives

Professional Introduction to Selumetinib (CAS No: 606143-52-6)

Selumetinib, a pharmaceutical compound with the chemical name 1-(4-fluorobenzyl)-4-[(3-methylpyrrolyl)methyl]-1H-pyrazole-5-carboxylic acid, is a significant molecule in the field of targeted cancer therapy. Its molecular structure and pharmacological properties have made it a subject of extensive research and clinical development. With a CAS number of 606143-52-6, this compound has garnered attention for its potential in treating various forms of cancer, particularly those driven by specific genetic mutations.

The development of Selumetinib was driven by the need for more precise and effective treatments for cancers that exhibit mutations in the KRAS pathway. KRAS is a well-known proto-oncogene that plays a crucial role in cell signaling and proliferation. Mutations in KRAS are frequently observed in cancers such as non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. Traditional chemotherapeutic agents often lack specificity, leading to significant side effects and limited efficacy. Selumetinib was designed to address this limitation by directly targeting the mutated KRAS protein.

One of the most notable features of Selumetinib is its ability to inhibit MEK1, a key enzyme in the MAPK signaling pathway that is often downstream of mutated KRAS. By blocking MEK1, Selumetinib disrupts the downstream signaling cascades that promote uncontrolled cell growth and survival. This mechanism has been validated through numerous preclinical studies, which have demonstrated its potential in reducing tumor size and inhibiting metastasis in animal models.

Recent clinical trials have provided further insights into the efficacy and safety of Selumetinib. In patients with advanced NSCLC harboring KRAS G12C mutations, Selumetinib showed promising results in terms of tumor response rates and progression-free survival. These findings have positioned Selumetinib as a potential treatment option for patients who have limited therapeutic choices due to resistance to other targeted therapies. The compound's ability to overcome resistance mechanisms by directly targeting the KRAS mutation has made it a cornerstone in the development of next-generation cancer therapies.

The pharmacokinetic profile of Selumetinib has also been extensively studied to optimize its therapeutic potential. The compound exhibits moderate oral bioavailability and a relatively long half-life, allowing for once-daily dosing regimens. This has improved patient compliance and convenience, making it a more practical option for long-term treatment. Additionally, studies have shown that Selumetinib has a manageable side effect profile, with fatigue, diarrhea, and rash being the most commonly reported adverse events.

Advances in drug delivery systems have further enhanced the therapeutic applications of Selumetinib. Nanoparticle-based formulations have been explored to improve drug solubility and target specificity, thereby increasing efficacy while minimizing systemic toxicity. These innovations are part of an ongoing effort to refine targeted therapies like Selumetinib, ensuring they reach their intended targets more effectively and with fewer side effects.

The integration of Selumetinib into clinical practice has also been facilitated by advancements in biomarker detection technologies. Techniques such as next-generation sequencing (NGS) have enabled the precise identification of KRAS mutations, allowing for more accurate patient selection. This personalized approach ensures that patients who are most likely to benefit from Selumetinib receive it, while those who are unlikely to respond can be spared unnecessary treatment exposure.

Ongoing research continues to explore the broader applications of Selumetinib beyond its initial indications. Studies are investigating its potential in combination therapies with other targeted agents or immunotherapy approaches. The goal is to develop synergistic treatment strategies that can overcome resistance mechanisms and provide more durable responses for patients with advanced cancers.

The development of Selumetinib represents a significant milestone in the field of precision medicine. By directly targeting specific genetic mutations, it exemplifies how advances in molecular biology and pharmacology can lead to more effective and personalized cancer treatments. As research progresses, it is anticipated that compounds like Selumetinib will play an increasingly important role in shaping the future of oncology care.

• 284486-91-5(1H-Benzimidazole-5-carboxylic acid,7-fluoro-6-[(4-iodo-2-methylphenyl)amino]-)
• 284030-47-3(1H-Benzimidazole-5-carboxamide,N-(cyclopropylmethoxy)-7-fluoro-6-[(4-iodo-2-methylphenyl)amino]-)
• 606093-59-8(Methyl 7-Fluoro-6-(phenylamino)-1H-benzodimidazole-5-carboxylate)
• 836602-05-2(1H-Benzimidazole-6-carboxamide,4-fluoro-N-(2-hydroxyethoxy)-5-[(4-iodo-2-methylphenyl)amino]-1-methyl-)
• 836602-24-5(1H-Benzimidazole-6-methanol,4-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-1-methyl-)
• 836602-33-6(1H-Benzimidazole-6-carboxylic acid,4-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-1-methyl-)
• 918321-20-7(methyl 5-amino-4-fluoro-1-methyl-1H-1,3-benzodiazole-6-carboxylate)
• 836602-35-8(1H-Benzimidazole-6-carboxylic acid,5-[(4-ethenyl-2-fluorophenyl)amino]-4-fluoro-1-methyl-, methyl ester)
• 284030-61-1(1H-Benzimidazole-5-carboxylic acid,7-fluoro-6-[(2-methylphenyl)amino]-, methyl ester)
• 836602-25-6(1H-Benzimidazole-6-carboxamide,5-[(4-ethyl-2-fluorophenyl)amino]-4-fluoro-1-methyl-)